Gambia vs Israel: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Gambia
0.1%
in 2024
Israel
0.1%
in 2024
Gambia rank
134th
Israel rank
134th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Gambia
- Israel
How they compare
Gambia currently reports 0.1% against 0.1% in Israel, a difference of 0.0%.
The two have swapped places 2 times across 10 shared years of data; in 2015 it was Israel ahead.
Gambia ranks 134th and Israel ranks 134th of 246 countries.
Across the 2 decades both report, Gambia averaged higher in 1 and Israel in 1.
Head to head by decade
| Decade | Gambia | Israel | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.3% | 0.1% | Israel |
| 2020s | 0.2% | 0.1% | 0.1% | Gambia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Gambia or Israel?
- Gambia, at 0.1% against 0.1% in Israel as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Gambia and Israel?
- 0.0%, with Gambia ahead.
- How many years of comparable data are there for Gambia and Israel?
- 10 years are reported by both, from 2015 to 2024.
- How do Gambia and Israel rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Gambia ranks 134th and Israel ranks 134th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.